Garuda - Garba Rujukan Digital

Profil Penggunaan Obat Antihipertensi pada Pasien Preeklamsia dan Eklampsia di RS X Nashwa Fika Nafillah; Bambang Tri Laksono; Fetri Lestari; Avi Admikowati
Bandung Conference Series: Pharmacy 595 - 602
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsp.v6i2.25267

Abstract. Preeclampsia and eclampsia are major causes of maternal morbidity and mortality that require effective blood pressure control. This study aims to describe patient characteristics and examine the profile of antihypertensive drug use based on monotherapy and combination therapy in patients with preeclampsia and eclampsia at Hospital X. The research method employed a retrospective, descriptive, observational study of 133 medical records. Data were analyzed descriptively and presented in tabular form. The results showed that the majority of patients were diagnosed with severe preeclampsia during their reproductive years (ages 25–44) and were in their third trimester of pregnancy. Based on the treatment profile, combination therapy was used more frequently than monotherapy. Overall, the most commonly used regimen was a three-drug combination (methyldopa + nifedipine + MgSO₄); the therapy administered was in accordance with clinical guidelines for managing preeclampsia and eclampsia at Hospital X. Abstrak. Preeklamsia dan eklampsia merupakan penyebab utama morbiditas dan mortalitas maternal yang memerlukan pengendalian tekanan darah secara efektif. Penelitian ini bertujuan untuk mendeskripsikan karakteristik pasien dan melihat profil penggunaan obat antihipertensi berdasarkan penggunaan monoterapi dan kombinasi obat pada pasien preeklamsia dan eklampsia di Rumah Sakit X. Metode penelitian menggunakan studi deskriptif observasional retrospektif terhadap 133 rekam medis. Data dianalisis secara deskriptif dan disajikan dalam bentuk tabel. Hasil penelitian menunjukkan bahwa mayoritas pasien didiagnosis mengalami preeklamsia berat pada usia reproduktif, yaitu 25-44 tahun dengan usia kehamilan trimester ketiga. Berdasarkan profil pengobatan, penggunaan terapi kombinasi lebih banyak dibandingkan monoterapi. Secara keseluruhan, obat yang paling sering digunakan adalah terapi kombinasi tiga obat (Metildopa + Nifedipin + MgSO4), terapi yang diberikan sudah sesuai dengan pedoman klinis dalam mengelola preeklamsia dan eklampsia di RS X.

Studi Literatur: Potensi Ekstrak Daun Kelor sebagai Terapi Topikal Luka Bakar Amelia Agustin; Bambang Tri Laksono; Arlina Prima Putri
Bandung Conference Series: Pharmacy 645 - 654
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsp.v6i2.25323

Abstract. Burn injuries are a type of tissue damage that require appropriate treatment to accelerate the healing process. Moringa leaves (Moringa oleifera Lam.) contain various bioactive compounds that may contribute to tissue regeneration during wound healing. Moringa oleifera Lam. (moringa) leaf is widely reported to contain flavonoids, tannins, saponins, alkaloids, and phenolic compounds with antioxidant, antimicrobial, and anti-inflammatory activity that support tissue regeneration. This study aims to map and synthesize scientific evidence on the potential of moringa leaf extract in various pharmaceutical dosage forms for burn wound therapy. A narrative literature review method was used, tracing national and international journal articles published between 2016 and 2026. The results show that moringa leaf extract has been formulated into ointments, creams, gels/hydrogels, and biocellulose patches, with effective concentrations generally ranging from 2.5% to 15%, and that its healing activity is associated with increased VEGF expression, TGF-β1 modulation, collagen deposition, and suppression of the inflammatory phase. It is concluded that moringa leaf extract shows strong and consistent potential as a natural active ingredient for burn wound care and merits further clinical development. Abstrak. Luka bakar merupakan jenis kerusakan jaringan yang harus ditangani secara tepat guna mempercepat proses penyembuhan. Daun kelor (Moringa oleifera Lam.) mengandung beberapa senyawa bioaktif yang dapat mempengaruhi proses regenerasi jaringan pada luka. Daun kelor (Moringa oleifera Lam.) dilaporkan secara luas mengandung flavonoid, tanin, saponin, alkaloid, dan senyawa fenolik dengan aktivitas antioksidan, antimikroba, dan anti-inflamasi yang mendukung regenerasi jaringan. Penelitian ini bertujuan memetakan dan mensintesis bukti ilmiah mengenai potensi ekstrak daun kelor dalam berbagai bentuk sediaan farmasi untuk terapi luka bakar. Metode yang digunakan adalah studi literatur naratif dengan menelusuri artikel jurnal nasional dan internasional terbitan tahun 2016-2026. Hasil kajian menunjukkan bahwa ekstrak daun kelor telah diformulasikan ke dalam salep, krim, gel/hidrogel, dan patch bioselulosa, dengan konsentrasi efektif umumnya berkisar 2,5% hingga 15%, dan aktivitas penyembuhannya berkaitan dengan peningkatan ekspresi VEGF, modulasi TGF-β1, deposisi kolagen, serta penekanan fase inflamasi. Disimpulkan bahwa ekstrak daun kelor memiliki potensi yang kuat dan konsisten sebagai bahan aktif alami untuk perawatan luka bakar dan layak dikembangkan lebih lanjut secara klinis.

Profil Simplisia dan Ekstrak Kulit Nanas dari Daerah Subang dengan Metode Maserasi Ira Kartika; Arlina Prima Putri; Bambang Tri Laksono
Bandung Conference Series: Pharmacy 701 - 708
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsp.v6i2.25582

Abstract. Pineapple peel (Ananas comosus L.) is an agricultural waste product containing various secondary metabolites such as flavonoids, saponins, tannins, and polyphenols as well as the enzyme bromelain, all of which have potential as raw materials for traditional medicines. This study aimed to obtain a profile of pineapple peel extract from the Subang region using the maceration method. Pineapple peel simplisia (dried raw material) was extracted with ethanol, followed by extract characterization involving organoleptic assessment, specific gravity determination, and phytochemical screening. The characterization results indicated that the extract met physical quality standards and contained secondary metabolites specifically flavonoids, saponins, tannins, and polyphenols capable of providing antioxidant, anti-inflammatory, and wound-healing activities. The maceration method was selected for its ability to preserve the stability of thermolabile compounds and yield an extract with a high content of active compounds. Based on these findings, pineapple peel extract holds potential for further development as a raw material for pharmaceutical preparations or natural-based health products. Abstrak. Kulit nanas (Ananas comosus L.) merupakan limbah pertanian yang masih mengandung berbagai senyawa metabolit sekunder, seperti flavonoid, saponin, tanin, polifenol, serta enzim bromelin yang berpotensi dimanfaatkan sebagai bahan baku obat tradisional. Penelitian ini bertujuan untuk memperoleh profil ekstrak kulit nanas yang berasal dari daerah Subang melalui metode maserasi. Simplisia kulit nanas diekstraksi menggunakan metode maserasi dengan pelarut etanol, kemudian dilakukan karakterisasi ekstrak meliputi pengamatan organoleptik, penetapan bobot jenis, dan skrining fitokimia. Hasil karakterisasi menunjukkan bahwa ekstrak memiliki karakteristik fisik yang memenuhi persyaratan serta mengandung senyawa metabolit sekunder berupa flavonoid, saponin, tanin, dan polifenol yang berpotensi memberikan aktivitas antioksidan, antiinflamasi, dan penyembuhan luka. Metode maserasi dipilih karena mampu mempertahankan kestabilan senyawa yang bersifat termolabil serta menghasilkan ekstrak dengan kandungan senyawa aktif yang baik. Berdasarkan hasil penelitian, ekstrak kulit nanas memiliki potensi untuk dikembangkan lebih lanjut sebagai bahan baku sediaan farmasi maupun produk kesehatan berbasis bahan alam.

Profil Penggunaan Obat-Antituberkulosis dan Anti-Retroviral pada Pasien Tuberkulosis-HIV Periode 2024-2025 Dinda Shafa Nabila; Bambang Tri Laksono; Umi Yuniarni
Bandung Conference Series: Pharmacy 779 - 788
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsp.v6i2.25723

Abstract. Tuberculosis (TB) is an opportunistic infection that frequently occurs in patients with Human Immunodeficiency Virus (HIV), requiring concurrent treatment with antituberculosis drugs (OAT) and antiretroviral drugs (ARV). This study aims to describe the characteristics of patients as well as the usage profiles of OAT, ARVs, and supportive medications among TB-HIV patients at Hospital X during the 2024–2025 period. The study employed a descriptive observational method with a retrospective approach based on medical record data. The sample was obtained using total sampling and included 75 patients who met the study criteria. Descriptive analysis was performed using frequency distributions and percentages. The results showed that the majority of patients were male (73.33%), aged 18–59 years (98.67%), and had extrapulmonary TB (61.33%). All patients received fixed-dose combination anti-tuberculosis therapy (2RHZE/4RH). The most commonly used ARV regimen was Tenofovir/Lamivudine/Efavirenz (TLE) (65.33%), followed by Tenofovir/Lamivudine/Dolutegravir (TLD) (29.33%). The most frequently administered adjunctive medications were vitamin B6 (74.67%) and co-trimoxazole (72.00%). The study results indicate that the use of OAT and ARVs was in accordance with national guidelines, with vitamin B6 and co-trimoxazole being the most commonly used adjunctive therapies. Abstrak. Tuberkulosis (TB) merupakan infeksi oportunistik yang sering terjadi pada pasien Human Immunodeficiency Virus (HIV), sehingga memerlukan terapi obat anti-tuberkulosis (OAT) dan antiretroviral (ARV) secara bersamaan. Penelitian ini bertujuan menggambarkan karakteristik pasien serta profil penggunaan OAT, ARV, dan obat pendukung pada pasien TB-HIV di Rumah Sakit X periode 2024–2025. Penelitian menggunakan metode observasional deskriptif dengan pendekatan retrospektif berdasarkan data rekam medis. Sampel diperoleh menggunakan metode total sampling dan melibatkan 75 pasien yang memenuhi kriteria penelitian. Analisis dilakukan secara deskriptif menggunakan distribusi frekuensi dan persentase. Hasil penelitian menunjukkan bahwa mayoritas pasien berjenis kelamin laki-laki (73,33%), berusia 18–59 tahun (98,67%), dan mengalami TB ekstraparu (61,33%). Seluruh pasien menerima OAT kombinasi dosis tetap (2RHZE/4RH). Regimen ARV yang paling banyak digunakan adalah Tenofovir/Lamivudin/Efavirenz (TLE) (65,33%), diikuti Tenofovir/Lamivudin/Dolutegravir (TLD) (29,33%). Obat pendukung yang paling sering diberikan adalah vitamin B6 (74,67%) dan kotrimoksazol (72,00%). Hasil penelitian menunjukkan bahwa penggunaan OAT dan ARV telah sesuai dengan pedoman nasional, dengan vitamin B6 dan kotrimoksazol sebagai terapi pendukung yang paling banyak digunakan.

Profil Regimen Kemoterapi pada Pasien Kanker Paru Stadium III Di RS X Periode 2023-2025 Adelia Nanda Maulana; Suwendar Suwendar; Bambang Tri Laksono
Bandung Conference Series: Pharmacy 807 - 816
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsp.v6i2.25747

Abstract. The prescription of chemotherapy (cytostatic drugs) as the primary treatment for lung cancer must be carried out with caution and under close supervision. This study aims to determine the rationale for regimen profile of chemotherapy to stage III lung cancer patients at X Hospital during the 2023–2025 period. The study was conducted as a descriptive observational study using a retrospective approach based on medical records of stage III lung cancer patients in the Inpatient Ward. . A total of 99 patients met the study criteria, with Non-Small Cell Lung Cancer (NSCLC) being the predominant type (92.9%). The Carboplatin–Paclitaxel regimen (45.5%) was found to be the most commonly used for NSCLC, while for Small Cell Lung Cancer (SCLC), it was the Etoposide–Carboplatin regimen (5.2%). The most commonly used supportive therapies included antiemetics, gastroprotectants, intravenous fluids and electrolytes, analgesics, corticosteroids, and bronchodilators. Abstrak. Peresepan kemoterapi (sitostatika) sebagai modalitas utama kanker paru harus dilakukan dengan kehati-hatian dan pengawasan ketat. Penelitian ini bertujuan untuk mengetahui profil regimen kemoterapi pada pasien kanker paru stadium III di Instalasi Rawat Inap RS X periode 2023–2025. Penelitian dilakukan secara observasional deskriptif dengan pendekatan retrospektif berdasarkan data rekam medis pasien kanker paru stadium III di Instalasi Rawat Inap. Sebanyak 99 pasien memenuhi kriteria penelitian, dengan dominasi Non-Small Cell Lung Cancer (NSCLC) (92,9%). Ditemukan Regimen kemoterapi Carboplatin - Paklitaksel (45,5%) paling banyak digunakan pada NSCLC, sedangkan pada Small Cell Lung Cancer (SCLC) adalah Etoposid Carboplatin (5,2%).. Terapi suportif yang paling banyak digunakan antara lain golongan antiemetik, gastroprotektor, cairan infus dan elektorlit, analgesik, koritkosteroid, serta bronkodilator

Kajian Potensi ROTD Pasien TB-HIV di RS X Periode 2024-2025 Annisa Nur Hasna Fauziyah; Bambang Tri Laksono; Umi Yuniarni
Bandung Conference Series: Pharmacy 843 - 852
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsp.v6i2.25853

Abstract. Tuberculosis (TB) and HIV co-infection increases the complexity of therapy because patients receive antituberculosis drugs (OAT) concurrently with antiretroviral therapy (ART) over a long period, thereby increasing the risk of Adverse Drug Reactions (ADR). This study aimed to determine the types and prevalence of potential ADR during therapy in TB-HIV patients. The study used a descriptive observational design with a cross-sectional approach, with data collected retrospectively from electronic medical records at Hospital X for the period 2024–2025, using a total sampling method based on inclusion and exclusion criteria. A total of 75 patients met the criteria, predominantly male (73.33%) and aged 18–59 years (98.67%), with pulmonary tuberculosis as the most com mon diagnosis (38.67%). All patients received first-line Fixed-Dose Combination (FDC) category-1 OAT, while the most commonly used ART regimen was TDF/3TC/EFV (65.33%). Of the 212 recorded ROTD events, the most frequently occurring were gastrointestinal disorders in the form of nausea and vomiting (20.57%), respiratory disorders in the form of cough (12.44%), and skin disorders in the form of itching (8.61%). These findings indicate that gastrointestinal, respiratory, and skin reactions are the most common adverse effects and require regular monitoring throughout combined TB-HIV therapy. Abstrak. Ko-infeksi tuberkulosis (TB) dan HIV meningkatkan kompleksitas terapi karena pasien mendapatkan obat antituberkulosis (OAT) secara bersamaan dengan terapi antiretroviral (ART) dalam jangka waktu panjang, sehingga meningkatkan risiko terjadinya Reaksi Obat Tidak Diinginkan (ROTD). Penelitian ini bertujuan untuk menentukan jenis dan prevalensi potensi ROTD selama terapi pada pasien TB-HIV. Penelitian menggunakan desain observasional deskriptif dengan pendekatan cross sectional, data diambil secara retrospektif melalui e-rekam medis di RS X periode 2024–2025, dengan metode total sampling berdasarkan kriteria inklusi dan eksklusi. Diperoleh 75 pasien yang memenuhi kriteria, didominasi laki-laki (73,33%) dan berusia 18–59 tahun (98,67%), dengan diagnosis terbanyak tuberkulosis paru (38,67%). Seluruh pasien menggunakan OAT Kombinasi Dosis Tetap (KDT) kategori-1, sedangkan regimen ART yang paling banyak digunakan adalah TDF/3TC/EFV (65,33%). Dari 212 kejadian ROTD yang tercatat, yang paling sering muncul adalah gangguan gastrointestinal berupa mual muntah (20,57%), gangguan pernapasan berupa batuk (12,44%), dan gangguan kulit berupa gatal (8,61%). Hasil penelitian ini menunjukkan bahwa reaksi gastrointestinal, pernapasan, dan kulit merupakan efek samping yang paling sering muncul dan perlu dipantau secara berkala selama terapi kombinasi TB-HIV berlangsung.

Title

Found 16 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 16 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 16 Documents
Search